InflaRx NV
IFRX0.802USD
-0.047-5.60%
종가 05/30, 16:00（ET）시세는 15분 지연됩니다
50.81M시가총액
손실P/E TTM
자세한 내용은 InflaRx NV 회사
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
회사 정보
회사 코드IFRX
회사 이름InflaRx NV
상장일Nov 16, 2017
설립일2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
직원 수74
유형Ordinary Share
회계 연도 종료Nov 16
주소Winzerlaer Str. 2
도시JENA
증권 거래소NASDAQ Global Select Consolidated
국가Germany
우편 번호07745
전화493641508180
웹사이트https://www.inflarx.de/
회사 코드IFRX
상장일Nov 16, 2017
설립일2017
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
수익 분석
통화: EUR업데이트 시간: Wed, Mar 5
통화: EUR업데이트 시간: Wed, Mar 5
FY2022
FY2021
FY2020
FY2019
데이터 없음
지역별EUR
이름
수익
비율
Germany
0.00
0.00%
United States
0.00
0.00%
사업별
지역별
데이터 없음
주주
업데이트 시간: Fri, May 16
업데이트 시간: Fri, May 16
주주 통계
유형
주주 통계
주주
비율
Suvretta Capital Management, LLC
9.66%
683 Capital Management LLC
3.91%
Guo (Renfeng M.D.)
2.62%
Eversept Partners, LP
2.50%
Morgan Stanley & Co. LLC
1.88%
Other
79.43%
주주 통계
주주
비율
Suvretta Capital Management, LLC
9.66%
683 Capital Management LLC
3.91%
Guo (Renfeng M.D.)
2.62%
Eversept Partners, LP
2.50%
Morgan Stanley & Co. LLC
1.88%
Other
79.43%
유형
주주
비율
Hedge Fund
20.40%
Individual Investor
6.44%
Investment Advisor
2.93%
Research Firm
2.34%
Investment Advisor/Hedge Fund
0.51%
Venture Capital
0.06%
Other
67.32%
기관 주식 보유
업데이트 시간: Mon, Mar 3
업데이트 시간: Mon, Mar 3
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
79
18.10M
26.96%
-3.72M
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
2023Q1
90
10.99M
24.57%
-8.39M
2022Q4
94
11.12M
24.89%
-8.55M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Suvretta Capital Management, LLC
5.73M
8.54%
--
--
Dec 31, 2024
683 Capital Management LLC
2.07M
3.08%
--
--
Dec 31, 2024
Guo (Renfeng M.D.)
1.76M
2.62%
+50.49K
+2.95%
Dec 31, 2023
Eversept Partners, LP
492.45K
0.73%
-1.13M
-69.64%
Dec 31, 2024
Morgan Stanley & Co. LLC
2.04M
3.04%
+1.37M
+205.16%
Dec 31, 2024
Riedemann (Niels C. M.D.)
1.07M
1.59%
--
--
Dec 31, 2023
Mark (Christian Kubler)
960.01K
1.43%
--
--
Dec 31, 2023
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
ALPS Medical Breakthroughs ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ALPS Medical Breakthroughs ETF
비율0%
Invesco Raymond James SB-1 Equity ETF
비율0%
Invesco NASDAQ Future Gen 200 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
